LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.
Risk and Volatility
LENZ Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.
Insider & Institutional Ownership
54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for LENZ Therapeutics and Lyra Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENZ Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Lyra Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
LENZ Therapeutics currently has a consensus price target of $17.50, indicating a potential upside of 473.77%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe LENZ Therapeutics is more favorable than Lyra Therapeutics.
Valuation and Earnings
This table compares LENZ Therapeutics and Lyra Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENZ Therapeutics | $12.36 million | 7.75 | -$82.13 million | ($4.49) | -0.68 |
| Lyra Therapeutics | $400,000.00 | 0.84 | -$28.92 million | ($19.15) | -0.01 |
Lyra Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares LENZ Therapeutics and Lyra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENZ Therapeutics | -1,134.97% | -56.10% | -51.63% |
| Lyra Therapeutics | N/A | N/A | N/A |
Summary
LENZ Therapeutics beats Lyra Therapeutics on 8 of the 13 factors compared between the two stocks.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
